APR 11, 2020 3:42 PM PDT

Remdesivir Improves COVID-19 Symptoms in 68% of Patients in Early Study

WRITTEN BY: Annie Lennon

An early analysis of remdesivir, a drug developed by pharmaceutical firm Gilead, has shown that it may have improved severe symptoms of COVID-19 in 68% of patients after 18 days. 

For the Gilead-funded study, doctors recruited 61 patients hospitalized with COVID-19 with oxygen saturation of 94% or less while breathing ambient air or receiving oxygen support. To receve remdesivir on a compassionate use basis (a program allowing the use of unapproved medicines when no other treatment options are available), on the first day of treatment, patients were administered 200mg of remesdevir, and then 100 mg daily on the remaining 9 days of treatment.

After 18 days of receiving the treatment, the doctors found just 53 patients who met the criteria following treatment for analysis. Among them, 36 (68%) had notable improvements in oxygen support class, including 17 patients receiving mechanical ventilation who were extubated. 25 patients were consequently discharged, while 7 died.

“We cannot draw definitive conclusions from these data, but the observations from this group of hospitalized patients who received remdesivir are hopeful,” said lead author of the study, Jonathon Grein, director of hospital epidemiology at Cedars-Sinai Medical Center in Los Angeles. 

Despite his optimism however, some remain skeptical of these results. Stephen Evans, a professor of pharmacoepidemiology at the London School of Hygiene and Tropical Medicine said, “The data from this paper are almost uninterpretable...There is some evidence suggesting efficacy, but we simply do not know what would have happened to these patients had they not been given the drug.”

Waiting to confirm the validity of these results are several large scale clinical trials currently investigating its effect against the virus. While one study conducted in China may be able to publish results later this month, another by the US National Institutes of Health may be able to report results in the next few weeks. Meanwhile, Gilead is sponsoring two more trials. 

“In studying remdesivir, the question is not just whether it is safe and effective against Covid-19, but in which patients it shows activity, how long should they receive treatment and at what stage of their disease would treatment be most beneficial,” said Daniel O’Day, Gilead’s chairman and chief executive officer. “Many answers are needed, which is why we need multiple types of studies involving many types of patients.”


Sources: Bloomberg, New England Journal of Medicine

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
SEP 29, 2020
Cardiology
Improving Acute Myocardial Ischemia Treatment with Nitro Fatty Acids
SEP 29, 2020
Improving Acute Myocardial Ischemia Treatment with Nitro Fatty Acids
Acute myocardial ischemia occurs when blood flow is restricted in the heart. This usually leads to cardiovascular issues ...
OCT 01, 2020
Immunology
Immune Cells and MS: The Good, the Bad, and the Maybe
OCT 01, 2020
Immune Cells and MS: The Good, the Bad, and the Maybe
Much like electrical wires that are encased in plastic insulating sheaths, nerve cells also are also surrounded by a sim ...
OCT 23, 2020
Drug Discovery & Development
Common Asthmatic Treatments Increase Risk of Bone Fractures
OCT 23, 2020
Common Asthmatic Treatments Increase Risk of Bone Fractures
A study published in the journal Thorax found that taking steroid inhalers or tablets for asthma treatment to control fl ...
NOV 08, 2020
Cell & Molecular Biology
Mouth Spray for Epidermolysis Bullosa in Development
NOV 08, 2020
Mouth Spray for Epidermolysis Bullosa in Development
Epidermolysis Bullosa (EB) is a rare genetic disorder that makes the skin incredibly fragile; it forms blisters and can ...
NOV 17, 2020
Immunology
6 Injections a Year Prevent HIV Infections
NOV 17, 2020
6 Injections a Year Prevent HIV Infections
Last year, around 1.7 million people became infected with HIV, with around half of these being women. Encouraging result ...
NOV 16, 2020
Drug Discovery & Development
A Change of Heart
NOV 16, 2020
A Change of Heart
For a long time cardiovascular issues related to the heart muscular wall have been addressed by therapeutics that target ...
Loading Comments...